Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

Conclusions The efficacy and safety of lanreotide in this study indicated its usefulness as a treatment option for Japanese NET patients. Trial registration: JapicCTI-132,375, JapicCTI-142,698.

http://link.springer.com/10.1007/s10637-017-0466-8

Source: Investigational New Drugs - May 3, 2017 Category: Drugs & Pharmacology Source Type: research